The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR)

Anticancer Research

Volumn 19, Issue 4 B, 1999, Pages 2885-2891

  Krishna, Rajesh ^a   Mayer, Lawrence D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; DRUG CARRIER; GLYCOPROTEIN P; LIPOSOME; VALSPODAR;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CELL; CHEMOSENSITIVITY; CLINICAL TRIAL; DATA ANALYSIS; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TOXICITY; ENCAPSULATION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLOSPORINS; HUMANS; LIPOSOMES; NEOPLASMS; P-GLYCOPROTEIN;

EID: 0033404026     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Gabizon A, and Papahadjopoulos D: Liposome formulations with prolonged circulation time in blood enhanced uptake by tumors. Proc Natl Acad Sci USA 85: 6949, 1988.
2. Gabizon A: Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 52: 891, 1992.
3. Forssen EA, Male-Brune R, Adler-Moore JP, Lee MJ, Schmidt PG, Krasieva TB, Shimizu S, and Tromberg BJ: Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res 56: 2066, 1996.
4. Mayer LD, Masin D, Nayar R, Boman NL and Bally MB: Pharmacology of liposomal vincristine in mice hearing L1210 ascitic and B16/BL6 solid tumors. Br J Cancer 71: 482, 1995.
5. Mayer LD, Tai LCL, Ko DSC, Masin D, Ginsberg RS, Cullis PR, and Bally MB: Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 49: 5922, 1989.
6. Van Hossel QGCM, Steerenberg PA, Crommelin DJA, van Dijk A, van Oort W, Klein S, Douze JM, de Wildt DJ, and Hillen FC: Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of DOX entrapped in stable liposomes in the LOU/M Wsl rat. Cancer Res 44: 3698, 1984.
7. Colombo T, Paz OG, and D'Incalci M: Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukemia. Br J Cancer 73: 866, 1996.
8. Mayer LD, Bally MB, Cullis PR, Wilson SL, and Emerman JT: Comparison of free and liposomal encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett 53: 183, 1990.
9. Webb MS, Harasym TO, Masin D, Bally MB, and Mayer LD: Sphingomyelin- cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 72: 896, 1995.
10. Landis SH, Murray T, Bolden S, and Wingo PA: Cancer statistics 1998, CA-A Cancer Journal for Clinicians 48: 6, 1998.
11. Gottesman MM: How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 54: 747, 1993.
12. Goasguen JE, Dossot J-M, Fardel O, Le Mee F, Le Gall E, Leblay R, LePrise PY, Chaperon J, and Fauchet R: Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 81: 2394, 1993.
13. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, and Fiere D: Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cell at diagnosis. Blood 79: 473, 1992.
14. Niehans GA, Jaszcz W, Brunetto V, Perri RT, Gajl-Peczalska K, Wick MR, Tsuruo T, and Bloomfield CD: Immunohisto-chemical identification of P-glycoprotein in previously untreated diffuse large cell and immunoblastic lymphomas. Cancer Res 52: 3768, 1992.
15. Gerlach JH, Bell DR, Karakousis C, Slocum HK, Kartner N, Rustum YM, Ling V, and Baker RM: P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol 5: 1452, 1987.
16. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, and Pastan I: Expression of a multidrug resistance gene in human tumors. J Natl Canc Inst 81: 116, 1989.
17. Chan HSL, Thorner P, Haddad G, and Ling V: Immunohisto-chemical detection of P- glycoprotein prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8: 689, 1990.
18. Chan HSL, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yeger H, and Ling V: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. New Eng J Med 325: 1608, 1991.
19. Bradley G, and Ling V: P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 13: 223, 1994.
20. Haak HR, van Seters AP, Moolenaar AJ, and Fleuren GJ: Expression of P- glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. Eur J Cancer 29A: 1036, 1993.
21. Finnegan MCM, Royds J, Goepel JR, Lorigan P, Hancock BW, and Goyns MH: MDR-1 expression in non-Hodgkin's lymphomas is unrelated to treatment intensity or response to therapy. Leukem Lymphom 18: 297, 1995.
22. Vergier B, Cany L, Bonnet F, Robert J, de Mascarel A, and Coindre JM: Expression of MDR1/P-glycoprotein in human sarcomas. Br J Cancer 68: 1221, 1993.
23. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE and Cowan K H: Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 33: 15544, 1986.
24. Lehnert M: Clinical multidrug resistance in cancer: A multifactorial problem. Eur J Cancer 32A: 912, 1996.
25. Tsuruo T, Hamada H, Sato S, and Heike Y: Inhibition of multidrug-resistant human tumor growth in athymic mice by anti-P-glycoprotein monoclonal antibodies. Jpn J Cancer Res 80: 627, 1989.
26. Yusa K, and Tsuruo T: Reversal mechanism of multidrug resistance by verapamil: Direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across plasma membrane of K562/ADM cells. Cancer Res 49: 5002, 1989.
27. Gottesman MM, and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochim 62: 385, 1993.
28. Hamada H, and Tsuruo T: Characterization of the ATPhase activity of the 170-to 180-kilodalton membrane glycoprotein (P-glycoprotein) association with multidrug resistance. Cancer Res 48: 4426, 1988.
29. Drori S, Eytan GD, and Assaraf YG: Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur J Biochem 228: 1020, 1995.
30. Drori S, Eytan GD, and Assaraf YG: Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur J Biochem 228: 1020, 1995.
31. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P. and Loor F: In-vivo circumvention of P-glycoprotein mediated multidrug resistance of tumor cells with PSC 833. Cancer Res 51: 4226, 1991.
32. Watanabe T: Kinetic analysis of hepatobiliary transport of vincristine in perfused rat liver. Possible roles of P-glycoprotein in biliary excretion of vincristine. J Hepatol 16: 77, 1992.
33. Watanabe T, Tsuge H, Oh-hara T, Naito M, and Tsuruo T: Comparative study on reversal efficacy of SDZ PSC 833, cyclosproin A and verapamil on multidrug resistance m vitro and in vivo. Acta Oncol 34: 235, 1995.
34. Lum B, and Gosland M: MDR expression in normal tissues: Pharmacologie implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am 9: 319, 1995.
35. Sonneveld P, and Marie J: Phase 1 study of SDZ PSC 833, a multidrug resistance modulating agent, in refractory multiple myeloma. Proc Am Assoc Cancer Res. 35: 358, 1994.
36. Van Kalken CK, van der Hoeven JJM, de Jong J et al: Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. Eur J Cancer 27: 739, 1991.
37. Dalmark M, Pals H, and Johnsen AH: Doxorubicin in combination with verapamil in advanced colorectal cancer: A phase II trial. Acta Oncol 30: 23, 1991.
38. Miller T, Dahlberg S, Grogan T, et al: Southwest Oncology Group clinical trials of chemosensitizers in non-Hodgkin's lymphomas. Anticancer Drugs 5: 73, 1994.
39. Krishna R, and Mayer LD: Liposomal doxorubicin circumvents PSC 833-tree drug interactions, resulting in effective therapy of multidrug resistant solid tumors. Cancer Res 57: 5246, 1997.